Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor.
作者信息
Kyvernitakis Andreas, Jabbour Elias, Torres Harrys A
机构信息
Department of Infectious Diseases, Infection Control and Employee Health.
出版信息
Clin Infect Dis. 2014 May;58(9):1342-4. doi: 10.1093/cid/ciu070. Epub 2014 Feb 5.
Abstract
摘要
相似文献
1
Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor.使用第一代丙型肝炎病毒蛋白酶抑制剂治疗6周后的持续病毒学应答。
Clin Infect Dis. 2014 May;58(9):1342-4. doi: 10.1093/cid/ciu070. Epub 2014 Feb 5.
2
[Conclusions].[结论]。
Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:49-50. doi: 10.1016/S0213-005X(13)70124-1.
3
[New triple therapy in chronic hepatitis C. Increased patient chances].[慢性丙型肝炎的新三联疗法。增加患者治愈几率]
MMW Fortschr Med. 2011 Sep 29;153(39):20.
4
[Therapy of hepatitis C: new inhibitors as hammers against HCV].[丙型肝炎的治疗：新型抑制剂作为对抗丙肝病毒的“锤子”]
MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:10-1.
5
[Treatment of hepatitis C infection. A revolution should not hide another].[丙型肝炎感染的治疗。一场革命不应掩盖另一场革命]
Presse Med. 2014 Apr;43(4 Pt 1):339-40. doi: 10.1016/j.lpm.2013.12.009. Epub 2014 Mar 21.
6
[A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].丙型肝炎治疗的新时代：“现在治疗可以个体化了”（医学博士德克·艾内克访谈）
MMW Fortschr Med. 2011 Jul 21;153(29-31):17.
7
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.基于丙型肝炎病毒蛋白酶抑制剂的三联疗法对慢性丙型肝炎1型感染的影响。
Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934.
8
Infectious diseases. First specific drugs raise hopes for hepatitis C.传染病。首批特效药物为丙型肝炎带来希望。
Science. 2011 Apr 8;332(6026):159-60. doi: 10.1126/science.332.6026.159.
9
[Telaprevir-induced pityriasis rubra pilaris].
Ann Dermatol Venereol. 2013 May;140(5):414-5. doi: 10.1016/j.annder.2013.01.336. Epub 2013 Mar 6.
10
Telaprevir-induced DRESS.特拉匹韦诱发的药物反应伴嗜酸性粒细胞增多和全身性症状（DRESS）。
J Drugs Dermatol. 2014 Feb;13(2):199-200.
本文引用的文献
1
Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.对于一名亚洲1型慢性丙型肝炎且IL28B基因型为CC的患者，使用特拉匹韦、聚乙二醇干扰素和利巴韦林治疗4周后出现持续病毒学应答。
Dig Dis Sci. 2014 Apr;59(4):737-9. doi: 10.1007/s10620-013-2903-7. Epub 2013 Oct 10.
2
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.慢性丙型肝炎患者接受特拉匹韦或博赛匹韦三联治疗时肾功能损害较为常见。
Hepatology. 2014 Jan;59(1):46-8. doi: 10.1002/hep.26602. Epub 2013 Nov 11.
3
Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus.重新探讨直接作用抗病毒药物治疗丙型肝炎时代持续病毒学应答的预测因素。
Clin Infect Dis. 2013 Jan;56(1):118-22. doi: 10.1093/cid/cis843. Epub 2012 Sep 28.
4
Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man.一名感染艾滋病毒的男性在接受基于特拉匹韦的治疗6个月后丙肝治愈。
Clin Infect Dis. 2013 Jan;56(1):163-4. doi: 10.1093/cid/cis826. Epub 2012 Sep 21.
5
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.1型慢性丙型肝炎病毒感染治疗的最新进展：美国肝病研究协会2011年实践指南
Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
6
Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.丙型肝炎患者的利巴韦林剂量应基于肾功能：一项群体药代动力学分析。
Ther Drug Monit. 2002 Dec;24(6):701-8. doi: 10.1097/00007691-200212000-00004.
Zotero 插件